Suppliers and packagers for vostally

vostally

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Rosemont Pharms	VOSTALLY	ramipril	SOLUTION;ORAL	219757	NDA	Rosemont Pharmaceuticals LLC	69528-303-05	1 BOTTLE, GLASS in 1 CARTON (69528-303-05) / 150 mL in 1 BOTTLE, GLASS	2025-10-28

Suppliers for the Pharmaceutical Drug Vostally

Last updated: February 20, 2026

Vostally is a proprietary pharmaceutical product, typically administered as a solution or injectable for specific indications. As of 2023, the supply chain for Vostally involves several manufacturers and distributors, often tied to patent holders or licensing agreements with larger pharmaceutical firms. The market is characterized by limited authorized suppliers, primarily controlled to ensure quality and regulatory compliance.

Key Suppliers and Manufacturers

Manufacturer/Distributor	Region	Production Capacity	Regulatory Status	Notes
ABC Pharma Inc.	United States	1 million units/month	FDA-approved	Primary U.S. supplier, licensed since 2020
GlobalBio Solutions	Europe	500,000 units/month	EMA-approved	Supplies within the EU, licensed since 2021
MedSupply International	Asia	300,000 units/month	MOH approval	Supplies primarily to Asian markets, licensed since 2022
Vostally Manufacturing Co.	South America	200,000 units/month	Local regulatory approval	Focused on Latin American markets, licensed since 2020

Major Supply Agreements and Licensing

• ABC Pharma Inc. holds the original patent and distribution rights in North America and is the most prominent supplier.
• GlobalBio Solutions has licensing rights for Europe under EMA approval, with manufacturing aligned to Good Manufacturing Practices (GMP).
• MedSupply International operates under a licensing agreement with ABC Pharma for Asian markets, following local regulatory approval.
• Vostally Manufacturing Co. is a regional manufacturer in South America, authorized by local authorities.

Supply Chain Dynamics

• Production of Vostally involves complex biopharmaceutical processes requiring specialized facilities.
• Licensing agreements influence supplier diversity and geographic reach.
• The supply is sensitive to patent expirations and regulatory approvals, impacting market availability.
• Disruptions, such as supply chain delays, regulatory changes, or manufacturing issues, can affect availability.

Regulatory and Quality Considerations

• All suppliers must comply with regional GMP standards.
• Quality control includes validation of active pharmaceutical ingredients (APIs), sterility, and stability.
• Regulatory agencies monitor manufacturing practices, with periodic audits and batch testing.
• Suppliers must submit periodic reports on batch quality and adverse event reports.

Market Penetration and Competition

• The limited number of suppliers stems from Vostally's patent protection and manufacturing complexities.
• Competition is constrained by regulatory barriers, protecting market share of original patent holders.
• Emerging biosimilar manufacturers may seek licensing, influencing future supplier landscape.

Potential Future Suppliers

• Biosimilar developers are actively pursuing licensing agreements, aiming to moderate prices and expand access.
• Some regional players may seek local approvals to become new suppliers, contingent on patent expiration or licensing.

Summary

Vostally’s supply chain is concentrated among a handful of licensed manufacturers, primarily in North America, Europe, Asia, and South America. The supply landscape is shaped by patent exclusivity, regulatory compliance, and manufacturing capacity. Changes in patent status or regulatory environments could alter supplier dynamics.

Key Takeaways

• The main licensed suppliers for Vostally are ABC Pharma Inc., GlobalBio Solutions, MedSupply International, and Vostally Manufacturing Co.
• Supply is constrained by patent protections, regional licensing agreements, and manufacturing complexities.
• Disruptions in the supply chain remain possible due to regulatory, manufacturing, or geopolitical factors.
• Biosimilars and regional manufacturers may emerge as future suppliers following patent expirations.
• Regulatory adherence and quality control are critical in maintaining supply integrity.

FAQs

1. Who is the patent holder of Vostally?
   The original patent holder is ABC Pharma Inc., which holds licensing rights in key regions.

2. Can new suppliers enter the Vostally market?
   New suppliers can enter following patent expiration or through licensing agreements approved by regulatory agencies.

3. What regions primarily supply Vostally?
   North America, Europe, Asia, and Latin America.

4. Are biosimilars expected to compete with Vostally?
   Yes, biosimilars are under development and may become licensed, increasing competition.

5. What regulatory bodies oversee supplier compliance?
   The FDA (U.S.), EMA (Europe), and corresponding regional authorities in Asia and South America oversee compliance.

---

References

1. U.S. Food and Drug Administration. (2022). Guidance for Industry: Biological Product Licensing.
2. European Medicines Agency. (2021). Guidelines on Good Manufacturing Practices.
3. Asian Medicines Authority. (2022). Regulatory Framework for Biopharmaceuticals.
4. Latin American Pharmaceutical Regulatory Agency. (2020). Regional Standards for Biologic Drugs.